Cargando…
“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061286/ https://www.ncbi.nlm.nih.gov/pubmed/35277655 http://dx.doi.org/10.1038/s41375-022-01537-w |
| _version_ | 1784698697738616832 |
|---|---|
| author | Rasmussen, Bengt Göhring, Gudrun Bernard, Elsa Nilsson, Lars Tobiasson, Magnus Jädersten, Martin Garelius, Hege Dybedal, Ingunn Grønbaek, Kirsten Ejerblad, Elisabeth Lorenz, Fryderyk Flogegård, Max Marcher, Claus Werenberg Öster Fernström, Annette Cavelier, Lucia Papaemmanuil, Elli Ebeling, Freja Kittang, Astrid Olsnes Nørgaard, Jan Maxwell Saft, Leonie Möllgård, Lars Hellström-Lindberg, Eva |
| author_facet | Rasmussen, Bengt Göhring, Gudrun Bernard, Elsa Nilsson, Lars Tobiasson, Magnus Jädersten, Martin Garelius, Hege Dybedal, Ingunn Grønbaek, Kirsten Ejerblad, Elisabeth Lorenz, Fryderyk Flogegård, Max Marcher, Claus Werenberg Öster Fernström, Annette Cavelier, Lucia Papaemmanuil, Elli Ebeling, Freja Kittang, Astrid Olsnes Nørgaard, Jan Maxwell Saft, Leonie Möllgård, Lars Hellström-Lindberg, Eva |
| author_sort | Rasmussen, Bengt |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9061286 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90612862022-05-04 “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” Rasmussen, Bengt Göhring, Gudrun Bernard, Elsa Nilsson, Lars Tobiasson, Magnus Jädersten, Martin Garelius, Hege Dybedal, Ingunn Grønbaek, Kirsten Ejerblad, Elisabeth Lorenz, Fryderyk Flogegård, Max Marcher, Claus Werenberg Öster Fernström, Annette Cavelier, Lucia Papaemmanuil, Elli Ebeling, Freja Kittang, Astrid Olsnes Nørgaard, Jan Maxwell Saft, Leonie Möllgård, Lars Hellström-Lindberg, Eva Leukemia Letter Nature Publishing Group UK 2022-03-11 2022 /pmc/articles/PMC9061286/ /pubmed/35277655 http://dx.doi.org/10.1038/s41375-022-01537-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Rasmussen, Bengt Göhring, Gudrun Bernard, Elsa Nilsson, Lars Tobiasson, Magnus Jädersten, Martin Garelius, Hege Dybedal, Ingunn Grønbaek, Kirsten Ejerblad, Elisabeth Lorenz, Fryderyk Flogegård, Max Marcher, Claus Werenberg Öster Fernström, Annette Cavelier, Lucia Papaemmanuil, Elli Ebeling, Freja Kittang, Astrid Olsnes Nørgaard, Jan Maxwell Saft, Leonie Möllgård, Lars Hellström-Lindberg, Eva “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” |
| title | “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” |
| title_full | “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” |
| title_fullStr | “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” |
| title_full_unstemmed | “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” |
| title_short | “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)” |
| title_sort | “randomized phase ii study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including del(5q)” |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9061286/ https://www.ncbi.nlm.nih.gov/pubmed/35277655 http://dx.doi.org/10.1038/s41375-022-01537-w |
| work_keys_str_mv | AT rasmussenbengt randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT gohringgudrun randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT bernardelsa randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT nilssonlars randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT tobiassonmagnus randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT jaderstenmartin randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT gareliushege randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT dybedalingunn randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT grønbaekkirsten randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT ejerbladelisabeth randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT lorenzfryderyk randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT flogegardmax randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT marcherclauswerenberg randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT osterfernstromannette randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT cavelierlucia randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT papaemmanuilelli randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT ebelingfreja randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT kittangastridolsnes randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT nørgaardjanmaxwell randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT saftleonie randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT mollgardlars randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q AT hellstromlindbergeva randomizedphaseiistudyofazacitidinelenalidomideinhigherriskmyelodysplasticsyndromesandacutemyeloidleukemiawithakaryotypeincludingdel5q |